<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective was to assess the efficacy of therapy with <z:chebi fb="1" ids="4315">danazol</z:chebi> in refractory <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo> associated with different <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with severe <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo> (platelet counts &lt; 40 x 10(9)/l) with a bone marrow biopsy showing megakaryocytes in <z:mpath ids='MPATH_458'>normal</z:mpath> or increased number and <z:mpath ids='MPATH_458'>normal</z:mpath> <z:mp ids='MP_0000002'>morphology</z:mp> were included if they fulfilled at least one of the following criteria: (a) <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> refractory to <z:chebi fb="0" ids="8382">prednisone</z:chebi> (&gt; or = 1 mg/kg/day during &gt; or = 4 weeks); (b) patients requiring an unacceptably high dose of <z:chebi fb="0" ids="8382">prednisone</z:chebi> for &gt; 2 months (<z:chebi fb="0" ids="8382">prednisone</z:chebi> dose &gt; or = 20 mg/day); (c) no response to at least another drug besides <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Other causes of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> were excluded </plain></SENT>
<SENT sid="3" pm="."><plain>They were treated with <z:chebi fb="1" ids="4315">danazol</z:chebi> (100-200 mg q.i.d.) and followed for at least 12 months </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients diagnosed with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, two with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and one with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> met the inclusion criteria </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them achieved acceptable platelet counts within the first 4 weeks of <z:chebi fb="1" ids="4315">danazol</z:chebi> therapy that allowed the <z:chebi fb="0" ids="8382">prednisone</z:chebi> dosage to be tapered </plain></SENT>
<SENT sid="6" pm="."><plain>No important side-effects related to <z:chebi fb="1" ids="4315">danazol</z:chebi> therapy were observed </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi> therapy seems to be a useful and well-tolerated treatment for refractory <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo> associated with different <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
</text></document>